Terms: = Lymphoma AND BTG1, P62324, 694, ENSG00000133639 AND Treatment
54 results:
1. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics.
Cao B; Sun C; Bi R; Liu Z; Jia Y; Cui W; Sun M; Yu B; Li X; Zhou X
BMC Med Genomics; 2024 Apr; 17(1):84. PubMed ID: 38609996
[TBL] [Abstract] [Full Text] [Related]
2. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.
Zou H; Liu W; Wang X; Wang Y; Wang C; Qiu C; Liu H; Shan D; Xie T; Huang W; Sui W; Yi S; An G; Xu Y; Ma T; Wang J; Qiu L; Zou D
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38443094
[TBL] [Abstract] [Full Text] [Related]
3. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract] [Full Text] [Related]
4. Differential expression of BCL11b and CDKN2A in CD30-positive peripheral T cell lymphoma: Retrospective study.
Wang Y; Zhang F; Gao N; Bu P; Cui W; Xi Y
Medicine (Baltimore); 2023 Nov; 102(46):e35531. PubMed ID: 37986346
[TBL] [Abstract] [Full Text] [Related]
5. Prevalence and predictors for fertility-related distress among 1010 young adults 1.5 years following cancer diagnosis - results from the population-based Fex-Can Cohort study.
Rodriguez-Wallberg KA; Ahlgren J; Smedby KE; Gorman JR; Hellman K; Henriksson R; Ståhl O; Wettergren L; Lampic C
Acta Oncol; 2023 Dec; 62(12):1599-1606. PubMed ID: 37909865
[TBL] [Abstract] [Full Text] [Related]
6. Axicabtagene ciloleucel compared to standard of care in Swedish patients with large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial.
Loftager ASL; Danø A; Eklund O; Vadgama S; Hedlof Kanje V; Munk E
J Med Econ; 2023; 26(1):1303-1317. PubMed ID: 37725082
[TBL] [Abstract] [Full Text] [Related]
7. Development and validation of a survival nomogram in patients with primary testicular diffuse large B-cell lymphoma.
Zhi Y; Bao S; Mao J; Chai G; Liu C; Zhu J
J Int Med Res; 2023 Sep; 51(9):3000605231197052. PubMed ID: 37676929
[TBL] [Abstract] [Full Text] [Related]
8. US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.
Matasar M; Masaquel A; S Ho R; Launonen A; Ng CD; Wang R; Fox D; Hossain F; Li J; Burke JM
J Med Econ; 2023; 26(1):1134-1144. PubMed ID: 37674384
[TBL] [Abstract] [Full Text] [Related]
9. Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI treatment in ALK-Rearranged Non-Small Cell Lung Cancer.
Zheng N; Zhang Y; Zeng Y; Ma Q; Zhang R; Zhao Q; Lu C; Tian J; Wang Z; Tang H; Luo N; Xiao H; He Y; Wu F; Li L
Target Oncol; 2023 Jul; 18(4):625-636. PubMed ID: 37351800
[TBL] [Abstract] [Full Text] [Related]
10. Survival differences between patients with de novo and relapsed/progressed advanced non-small cell lung cancer without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.
Oh BC; Cho AR; Nam JH; Yang SY; Kim MJ; Kwon SH; Lee EK
BMC Cancer; 2023 May; 23(1):482. PubMed ID: 37248452
[TBL] [Abstract] [Full Text] [Related]
11. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
[TBL] [Abstract] [Full Text] [Related]
12. Vincristine and dexamethasone pulses in addition to maintenance therapy among pediatric acute lymphoblastic leukemia (GD-ALL-2008): An open-label, multicentre, randomized, phase III clinical trial.
Qiu KY; Wang JY; Huang LB; Li CG; Xu LH; Liu RY; Chen HQ; Ruan YS; Zhen ZJ; Li CK; Fang JP
Am J Hematol; 2023 Jun; 98(6):869-880. PubMed ID: 36877527
[TBL] [Abstract] [Full Text] [Related]
13. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell lymphoma.
Vijenthira A; Kuruvilla J; Crump M; Jain M; Prica A
J Clin Oncol; 2023 Mar; 41(8):1577-1589. PubMed ID: 36315922
[TBL] [Abstract] [Full Text] [Related]
14. Prevalence and risk factors for sexual dysfunction in young women following a cancer diagnosis - a population-based study.
Wettergren L; Eriksson LE; Bergström C; Hedman C; Ahlgren J; Smedby KE; Hellman K; Henriksson R; Lampic C
Acta Oncol; 2022 Oct; 61(10):1165-1172. PubMed ID: 36176069
[TBL] [Abstract] [Full Text] [Related]
15. Emerging role of anti-proliferative protein btg1 and BTG2.
Kim SH; Jung IR; Hwang SS
BMB Rep; 2022 Aug; 55(8):380-388. PubMed ID: 35880434
[TBL] [Abstract] [Full Text] [Related]
16. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends.
Huang J; Chan SC; Lok V; Zhang L; Lucero-Prisno DE; Xu W; Zheng ZJ; Elcarte E; Withers M; Wong MCS;
Lancet Haematol; 2022 Sep; 9(9):e670-e677. PubMed ID: 35843248
[TBL] [Abstract] [Full Text] [Related]
17. Liver Transplant Recipients Who Survive for More Than 10 Years: A Long-Term Survey.
Ayvazoğlu Soy EH; Akdur A; Karakaya E; Moray G; Haberal M
Exp Clin Transplant; 2022 Mar; 20(Suppl 1):20-23. PubMed ID: 35384803
[TBL] [Abstract] [Full Text] [Related]
18. The outcome of watchful waiting in patients with previously treated follicular lymphoma.
Fujino T; Maruyama D; Maeshima AM; Saito Y; Ida H; Hosoba R; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Kuroda J; Izutsu K
Cancer Med; 2022 May; 11(10):2106-2116. PubMed ID: 35129305
[TBL] [Abstract] [Full Text] [Related]
19. Economic evaluation of polatuzumab-bendamustine-rituximab
Calamia M; McBride A; Abraham I
J Med Econ; 2021 Nov; 24(sup1):14-24. PubMed ID: 34866523
[TBL] [Abstract] [Full Text] [Related]
20. Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.
Balasubramanian S; Hodkinson B; Schuster SJ; Fowler NH; Trotman J; Hess G; Cheson BD; Schaffer M; Sun S; Deshpande S; Vermeulen J; Salles G; Gopal AK
Cancer Med; 2022 Jan; 11(1):61-73. PubMed ID: 34791836
[TBL] [Abstract] [Full Text] [Related]
[Next]
